JPMDL Creates Separate Track For GLP-1 Eye Injury Cases In Pa. Federal Court
WASHINGTON, D.C. — The U.S. Judicial Panel on Multidistrict Litigation on Dec. 15 agreed to centralize cases alleging that the use of glucagon-like peptide-I receptor agonist XE "glucagon-like peptide-I receptor agonist"...To view the full article, register now.
Already a subscriber? Click here to view full article